Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    A site revision tag v3.4.2 was added and a government funding status notice (and an earlier revision note) was removed; there are no changes to the study data or page content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-11T14:06:27.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide notice about government funding lapse and NIH Clinical Center status was added, along with a version update (Revision: v3.4.1).
    Difference
    0.5%
    Check dated 2026-02-04T10:12:20.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary toggle and minor wording/capitalization updates to QC labels and the revision text. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T06:01:32.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Added Revision: v3.3.4 and removed Revision: v3.3.3 on the page.
    Difference
    0.1%
    Check dated 2026-01-14T02:10:33.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Location information on the study page was updated to include a standalone 'Locations' section with Louisiana, replacing the former 'Louisiana Locations' label. The 'HHS Vulnerability Disclosure' link was removed from the page footer.
    Difference
    0.2%
    Check dated 2025-12-23T09:25:58.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.3.2, replacing Revision: v3.3.1. This appears to be a site revision update and does not alter the study details.
    Difference
    0.1%
    Check dated 2025-12-01T17:29:56.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.